IMNM

Immunome, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Bienaime Jean JacquesDirector
$194k10k shares
SellJun 5, 2026
$19.41
$22.11
Bienaime Jean JacquesDirector
$117k6k shares
BuyJun 5, 2026
$19.48
$22.11
Bienaime Jean JacquesDirector
$68k3.5k shares
BuyJun 5, 2026
$19.46
$22.11
Bienaime Jean JacquesDirector
$19k1k shares
BuyJun 5, 2026
$19.27
$22.11
Bienaime Jean JacquesDirector
$9.7k500 shares
SellJun 5, 2026
$19.44
$22.11
Higgins JackChief Scientific Officer
$49k3.5k shares
SellAug 15, 2024
$13.93
--

News

gurufocus.comImmunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumorsgurufocus.comJun 11businesswire.comImmunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumorsbusinesswire.comJun 11seekingalpha.comImmunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 9seekingalpha.comImmunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesisseekingalpha.comJun 9zacks.com4 Biotech Stocks Investors Should Watch in 2026zacks.comJun 5